New Drugs in Pediatric Oncology - Where Do We Stand Now - Pitfalls and Hurdles

ŠTĚRBA, Jaroslav. New Drugs in Pediatric Oncology - Where Do We Stand Now - Pitfalls and Hurdles. In 7th Midsummer Meeting on Pediatric Hematology, Oncology and Stem Cell Transplantation. 2015. ISBN 978-80-7471-110-7.

Basic information

Original name

New Drugs in Pediatric Oncology - Where Do We Stand Now - Pitfalls and Hurdles

Authors

ŠTĚRBA, Jaroslav (203 Czech Republic, guarantor, belonging to the institution)

Edition

7th Midsummer Meeting on Pediatric Hematology, Oncology and Stem Cell Transplantation, 2015

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/15:00084950

Organization unit

Faculty of Medicine

ISBN

978-80-7471-110-7

Keywords in English

cancer in childhood

Tags

EL OK

---

Abstract

V originále

Cancer is still leading cause of death in childhood among diseases. Encouraging progress has been made in the treatment of childhood malignancies during 70th till 90th, and maximum tolerated doses (MTD) of chemotherapy plus radiotherapy contributed significantly, together with improvements in supportive care, to improved overall survival. However, about 20% of children will die due to their malignancy and significant proportion of survivors suffers from treatment related toxicities, including secondary malignancies. Thus, there is clearly an unmet need for new drugs to improve survival and reduce treatment-associated toxicities in contemporary pediatric oncology. However, drug development in pediatric oncology is very complex and has specific requirements with regard to the patient population, regulatory background and presents several unique challenges that need addressing.